Foghorn Therapeutics Inc. Stock or Unit Option Plan Expense
Foghorn Therapeutics Inc. (FHTX) reported Stock or Unit Option Plan Expense of $14.34 million for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-09.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:StockOptionPlanExpense · last filed 2023-03-09
- Foghorn Therapeutics Inc. stock or unit option plan expense for the quarter ending 2022-03-31 was $3.24M, a 71.82% increase year-over-year.
- Foghorn Therapeutics Inc. stock or unit option plan expense for the quarter ending 2021-12-31 was $2.08M, a 93.32% increase year-over-year.
- Foghorn Therapeutics Inc. stock or unit option plan expense for the quarter ending 2021-03-31 was $1.89M.
- Foghorn Therapeutics Inc. stock or unit option plan expense for the quarter ending 2020-12-31 was $1.08M.
- Foghorn Therapeutics Inc. stock or unit option plan expense for fiscal 2022 was $14.34M, a 70.99% increase from fiscal 2021.
- Foghorn Therapeutics Inc. stock or unit option plan expense for fiscal 2021 was $8.38M, a 183.15% increase from fiscal 2020.
- Foghorn Therapeutics Inc. stock or unit option plan expense for fiscal 2020 was $2.96M.
| Period end | Stock or Unit Option Plan Expense 3 month | Stock or Unit Option Plan Expense 6 month | Stock or Unit Option Plan Expense 9 month | Stock or Unit Option Plan Expense 12 month |
|---|---|---|---|---|
| 2022-12-31 | $14.34M 10-K · filed 2023-03-09 | |||
| 2022-03-31 | $3.24M 10-Q · filed 2022-05-09 | $5.33M derived: sum of 2 quarters · filed 2023-03-09 | ||
| 2021-12-31 | $2.08M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $8.38M 10-K · filed 2023-03-09 | ||
| 2021-09-30 | $6.30M 10-Q · filed 2021-11-09 | |||
| 2021-03-31 | $1.89M 10-Q · filed 2022-05-09 | $2.97M derived: sum of 2 quarters · filed 2022-08-09 | ||
| 2020-12-31 | $1.08M derived: 10-K/A 12 month − 10-Q 9 month · filed 2022-08-09 | $2.96M 10-K/A · filed 2022-08-09 | ||
| 2020-09-30 | $1.88M 10-Q · filed 2021-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |